Gemini Therapeutics

OverviewSuggest Edit

Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. The Company's therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and its broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies.
TypePrivate
Founded2015
HQCambridge, MA, US
Websitegeminitherapeutics.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Apr 2022)34(-5%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Gemini Therapeutics

David Lubner

David Lubner

Independent Director
Jason Meyenburg

Jason Meyenburg

Chief Executive Officer
Samuel Barone

Samuel Barone

Chief Medical Officer
Brian Piekos

Brian Piekos

Chief Financial Officer
Scott Lauder

Scott Lauder

Chief Technology Officer
Precillia Redmond

Precillia Redmond

Chief People Officer
Show more

Gemini Therapeutics Office Locations

Gemini Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
300 One
Show all (1)

Gemini Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Gemini Therapeutics total Funding

$44.5 m

Gemini Therapeutics latest funding size

$42.5 m

Time since last funding

5 years ago

Gemini Therapeutics investors

Gemini Therapeutics's latest funding round in October 2017 was reported to be $42.5 m. In total, Gemini Therapeutics has raised $44.5 m
Show all financial metrics

Gemini Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Gemini Therapeutics Online and Social Media Presence

Embed Graph

Gemini Therapeutics News and Updates

Thinking about buying stock in BELLUS Health, Gemini Therapeutics, BlackBerry, Reliance Global Group, or Ocugen?

NEW YORK, Dec. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLU, GMTX, BB, RELI, and OCGN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Gemini Therapeutics Blogs

Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy

Topline Data Expected in 2H 2021 The post Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy appeared first on Gemini Therapeutics.

Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for the Treatment of Dry Age-Related Macular Degeneration (AMD) in Patients with Complement Factor H (CFH) Loss of Function Gene Variants

CAMBRIDGE, Mass. – January 7, 2021 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that GEM103, the Company’s investigational treatment for dry AMD, has been granted Fa…

Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study

Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that the Phase 1 study of GEM103, the Company’s investigational treatment for dry AMD, met all its endpoints. The post Gem…

Gemini Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass. – November 10, 2020 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenberg, Chief Executive Officer of Gemini Therapeutics, is scheduled …

Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration

CAMBRIDGE, Mass. and SAN FRANCISCO – October 15, 2020 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), and FS Development Corp. (Nasdaq: FSDC), a special purpose acquisition company spo…

Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration

Enrollment completed in Phase 1 SAD study in patients with high-risk genetic variants for dry AMD. Phase 1 topline results demonstrate promising safety profile, with no treatment-related adverse events as well as PK and biomarker changes in genetically defined dry AMD. CAMBRIDGE, Mass. —(BUSINESS WI…
Show more

Gemini Therapeutics Frequently Asked Questions

  • When was Gemini Therapeutics founded?

    Gemini Therapeutics was founded in 2015.

  • Who are Gemini Therapeutics key executives?

    Gemini Therapeutics's key executives are David Lubner, Jason Meyenburg and Samuel Barone.

  • How many employees does Gemini Therapeutics have?

    Gemini Therapeutics has 34 employees.

  • Who are Gemini Therapeutics competitors?

    Competitors of Gemini Therapeutics include Othram, Cradle Genomics and Heart Genetics.

  • Where is Gemini Therapeutics headquarters?

    Gemini Therapeutics headquarters is located at 300 One, Cambridge.

  • Where are Gemini Therapeutics offices?

    Gemini Therapeutics has an office in Cambridge.

  • How many offices does Gemini Therapeutics have?

    Gemini Therapeutics has 1 office.